

PRODUCT INFORMATION
NORFLOXACIN SANDOZ 400mg FILM-COATED TABLETS

NAME OF THE MEDICINE

Norfloxacin

1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid



CAS [70458-96-7]

Empirical formula: C₁₆H₁₈FN₃O₃

MW: 319.3

DESCRIPTION

A white or pale yellow, hygroscopic, photosensitive crystalline powder, very slightly soluble in water, slightly soluble in acetone and in alcohol.

In addition to norfloxacin, Norfloxacin Sandoz film coated tablets contain: microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide, propylene glycol, lactose, macrogol 4000, and purified talc.

Norfloxacin, a fluoroquinolone, differs from quinolones by having a fluorine atom at the 6 position and a piperazine moiety at the 7 position. Examples of antibacterial medicines which are quinolones include nalidixic acid and cinoxacin.

PHARMACOLOGY

Pharmacodynamics

Norfloxacin has *in vitro* activity against a broad spectrum of Gram-negative and some Gram-positive aerobic bacteria.

Norfloxacin inhibits bacterial deoxyribonucleic acid synthesis and is bactericidal. At the molecular level three specific events are attributed to norfloxacin in *Escherichia coli* cells: inhibition of the ATP dependent DNA supercoiling reaction catalysed by

DNA gyrase; inhibition of the relaxation of supercoiled DNA; promotion of double stranded DNA breakage.

Resistance to norfloxacin due to spontaneous mutation *in vitro* is a rare occurrence (range: 10^{-9} to 10^{-12} cells). Resistance of the organism has developed during therapy with norfloxacin in less than 1% of patients treated. Organisms in which development of resistance is greatest are the following: *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Acinetobacter* sp., *Enterococci*. For this reason, when there is a lack of satisfactory clinical response, culture and susceptibility testing should be repeated.

Norfloxacin is active *in vitro* against the following organisms:

- **Bacteria found in urinary tract infections:**

Aerobic bacteria:

Gram-positive bacteria including *Streptococcus faecalis* (*Enterococcus*), *Staphylococcus aureus*, *Staph. epidermidis*, *Staph. saprophyticus*.

Gram-negative bacteria including *Citrobacter diversus*, *C. freundii*, *Enterobacter cloacae*, *Escherichia coli*, *Klebsiella oxytoca*, *K. pneumoniae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*.

- **Bacteria found in gastrointestinal infections:**

Shigella, *E. coli*, *Salmonella typhi*.

In addition, norfloxacin is active against *Neisseria gonorrhoeae*.

Norfloxacin is not generally active against obligate anaerobes.

Nalidixic acid resistant organisms are generally susceptible to norfloxacin *in vitro*; however, these organisms may have higher minimum inhibitory concentrations (MIC) to norfloxacin than nalidixic acid susceptible strains. There is generally no cross resistance between norfloxacin and other classes of antibacterial agents. Therefore, norfloxacin often demonstrates activity against indicated organisms resistant to the aminoglycosides (including gentamicin), penicillins, cephalosporins, tetracyclines, macrolides and sulfonamides, including combinations of sulfamethoxazole and trimethoprim. Antagonism has been demonstrated *in vitro* between norfloxacin and nitrofurantoin.

Susceptibility tests

Quantitative methods that require measurement of zone diameters give precise estimates of bacterial susceptibility. One such procedure has been recommended for use with discs to test susceptibility to norfloxacin.

Reports from the laboratory giving results of the standard single disc susceptibility test with a 10µg norfloxacin disc should be interpreted according to the following criteria. Susceptible organisms produce zone diameters of 13mm or greater, indicating that the test organism is likely to respond to therapy.

Resistant organisms produce zone diameters of 12mm or less, indicating that other therapy should be selected. A bacterial isolate may be considered susceptible if the MIC value for norfloxacin is equal to or less than 16µg/mL. Organisms are considered resistant if the MIC is equal to or greater than 32µg/mL.

The standardised quality control procedure requires use of control organisms. The 10µg norfloxacin disc should give the zone diameters listed in Table 1 for the quality control strains. Please refer to Table 1.

Table 1

<u>Organism</u>	<u>ATCC</u>	<u>Zone size range</u>
<i>Escherichia coli</i>	25922	28 – 35mm
<i>Pseudomonas aeruginosa</i>	27853	22 – 29mm
<i>Staphylococcus aureus</i>	25923	17 – 28mm

Dilution susceptibility tests should give MICs between the ranges listed in Table 2 for the quality control strains. Please refer to Table 2.

Table 2

<u>Organism</u>	<u>ATCC</u>	<u>MIC (µg/mL)</u>
<i>Escherichia coli</i>	25922	0.03 – 0.125
<i>Staphylococcus aureus</i>	29213	0.5 – 2.0
<i>Streptococcus faecalis</i>	29212	2.0 – 8.0
<i>Pseudomonas aeruginosa</i>	27853	1.0 – 4.0

Based on urinary concentrations of norfloxacin achieved in humans, breakpoint criteria have been established as listed in Table 3. Please refer to Table 3.

Table 3

<u>Category</u>	<u>Zone diameter (mm)</u>	<u>Recommended MIC breakpoint (µg/mL)</u>
Susceptible	≥ 13	≤ 16
Resistant	≤ 12	≥ 32

Norfloxacin susceptibility test results should not be used to predict susceptibility to other less potent quinolone antibacterial agents such as nalidixic acid.

Animal pharmacology

Norfloxacin and related medicines have been shown to cause arthropathy in immature animals of most species tested (see PRECAUTIONS).

Crystalluria has occurred in laboratory animals tested with norfloxacin. In dogs, needle shaped medicine crystals were seen in the urine at doses of 50mg/kg/day. In rats, crystals were reported following doses of 200mg/kg/day.

Embryo lethality and slight maternotoxicity (vomiting and anorexia) were observed in cynomolgus monkeys at doses of 150mg/kg/day or higher.

Ocular toxicity, seen with some related medicines, was not observed in any norfloxacin treated animals.

Pharmacokinetics

In fasting healthy volunteers, approximately 30 to 40% of an oral dose of norfloxacin is absorbed. Absorption is rapid following single doses of 200 and 400mg. At the respective doses, mean peak serum and plasma concentrations of 0.8 and 1.5 µg/mL are attained approximately one hour after dosing. The presence of food may decrease absorption. The effective half-life of norfloxacin in serum and plasma is three to four hours. Steady state concentrations of norfloxacin will be attained within two days of dosing.

The absorbed norfloxacin is eliminated mainly through renal excretion. Renal excretion occurs by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance (approximately 275mL/minute). Within 24 hours of medicine administration, 26 to 32% of the administered dose is recovered in the urine as norfloxacin with an additional 5 to 8% being recovered in the urine as six metabolites of considerably less antimicrobial potency. However, urinary recovery may occasionally be very low. Only a small percentage (less than 1%) of the dose is recovered thereafter.

Two to three hours after a single 400mg dose, urinary concentrations of 200µg/mL or more are attained in the urine. In healthy volunteers, mean urinary concentrations of norfloxacin remain above 30µg/mL for approximately 12 hours following a 400mg dose. The urinary pH may affect the solubility of norfloxacin. Norfloxacin is least soluble at urinary pH of 7.5 with solubility increasing at pHs above and below this value.

The disposition of norfloxacin in patients with creatinine clearance rates greater than 30mL/minute/1.73m² is similar to that in healthy volunteers. In patients with creatinine clearance rates equal to or less than 30mL/minute/1.73m², the renal elimination of norfloxacin decreases so that the effective serum half-life is 8.6 to 11.5 hours. In these patients, alteration of dosage is necessary (see DOSAGE AND ADMINISTRATION). Medicine absorption appears unaffected by decreasing renal function.

In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), norfloxacin is eliminated more slowly because of their slightly decreased renal function. Medicine absorption appears unaffected. The effective half-life of norfloxacin in these elderly subjects is four hours.

Faecal recovery accounts for another 30% of the administered dose. This represents the unabsorbed medicine along with a small contribution through biliary excretion. After a single 400mg dose of norfloxacin, mean antimicrobial activities equivalent to 278, 773 and 82µg of norfloxacin/g of faeces were obtained at 12, 24 and 48 hours, respectively.

The serum protein binding of norfloxacin is between 10 and 15%.

INDICATIONS

Treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms.

Treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea.

Note. Specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants.

Suppression, in adults, of chronic, recurrent urinary tract infection.

CONTRAINDICATIONS

Hypersensitivity to any component of this product or any chemically related quinolone antibacterials.

Norfloxacin is contraindicated in patients with a history of tendinitis and/or tendon rupture related to fluoroquinolone administration

Children.

Pregnancy (see PRECAUTIONS).

PRECAUTIONS

Hypersensitivity reactions

Serious and occasionally fatal hypersensitivity anaphylactic or anaphylactoid) reactions, some following the first dose, have been reported in patients receiving quinolone therapy. In such cases, therapy with Norfloxacin must be discontinued immediately and appropriate emergency action must be started (e.g. antihistamines, glucocorticosteroids, sympathomimetics and ventilation if necessary).

Peripheral neuropathy

Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones which can be rapid in its onset. Norfloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.

Arthropathy

The oral administration of single doses of norfloxacin 100mg/kg caused lameness in immature dogs. Histological examination of the weight bearing joints of these dogs revealed permanent lesions of the cartilage. Related medicines (e.g. nalidixic acid and

cinoxacin) also produced erosions of the cartilage in weight bearing joints and other signs of arthropathy in immature animals of various species.

Crystalluria

Needle shaped crystals were found in the urine of some volunteers who received either placebo, norfloxacin 800mg or norfloxacin 1,600mg (at or twice the recommended daily dose, respectively) while participating in a double blind, crossover study comparing single doses of norfloxacin with placebo. While crystalluria is not expected to occur under usual conditions with a dosage regimen of 400mg twice daily, as a precaution the daily recommended dosage should not be exceeded and the patient should drink sufficient fluids to ensure a proper state of hydration and adequate urinary output.

Alteration in dosage regimen is necessary for patients with impaired renal function (see DOSAGE AND ADMINISTRATION).

Renal Impairment

Norfloxacin Sandoz is suitable for the treatment of patients with renal impairment; however, since Norfloxacin Sandoz is primarily excreted by the kidney, urinary levels may be significantly compromised by severe renal dysfunction (see DOSAGE AND ADMINISTRATION).

Nervous system

The effects of norfloxacin on brain function or on the electrical activity of the brain have not been tested. Convulsions have been reported rarely in patients receiving norfloxacin. As with other organic acids, norfloxacin should be used with caution in individuals with a history of convulsions or known factors that predispose to seizures.

Quinolone, including norfloxacin, may exacerbate the signs of myasthenia gravis and lead to life threatening weakness of the respiratory muscles. Caution should be exercised when using quinolones, including norfloxacin, in patients with myasthenia gravis (see ADVERSE EFFECTS).

Antibiotic-associated colitis

Antibiotic associated pseudomembranous colitis has been reported with nearly all antibiotics including norfloxacin. A toxin produced with *Clostridium difficile* appears to be the primary cause. The severity of the colitis may range from mild to lifethreatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against *C. difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis, eg, opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.

Photosensitivity

Photosensitivity reactions have been observed in patients who are exposed to excessive sunlight while receiving some members of this medicine class. Excessive sunlight should be avoided. Therapy should be discontinued if photosensitivity occurs.

Vision disorders

If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see ADVERSE EFFECTS).

Effect on tendons

Tendon inflammation and rupture that required surgical repair or resulted in prolonged disability have been reported with fluoroquinolone therapy including norfloxacin. This risk is further increased in elderly patients and those treated concurrently with corticosteroids. Tendon rupture can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported. Norfloxacin should be discontinued at the first sign of pain, swelling, inflammation, or rupture of a tendon. Patients are advised to inform their health professional, rest the affected limb(s) and refrain from exercise.

Haemolytic reactions

Rarely, haemolytic reactions have been reported in patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin (see ADVERSE EFFECTS).

Cardiac disorders

Some quinolones have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmias. During postmarketing surveillance, extremely rare cases of torsades de pointes have been reported in patients taking norfloxacin. These reports generally involve patients who had other concurrent medical conditions and the relationship to norfloxacin has not yet been established. Among medicines known to cause prolongation of the QT interval, the risk of arrhythmias may be reduced by avoiding use in the presence of hypokalaemia, significant bradycardia, or concurrent treatment with class IA or class III antiarrhythmic agents. Quinolones should also be used with caution in patients using cisapride, erythromycin, antipsychotics, tricyclic antidepressants or have any personal or family history of QTc prolongation.

Carcinogenicity

Information is not available at present on the carcinogenic potential of norfloxacin.

Genotoxicity

Norfloxacin was tested for mutagenic activity in a number of *in vivo* and *in vitro* tests. Norfloxacin had no mutagenic effect in the dominant lethal test in mice and did not cause chromosomal aberrations in hamsters or rats at 500 to 1,000mg/kg/day. Norfloxacin had no mutagenic activity *in vitro* in the Ames microbial mutagen test and V-79 mammalian cell assay. Although norfloxacin was weakly positive in the Rec-assay for DNA repair, all other mutagenic assays were negative including a more sensitive test (V-79).

Effects on fertility

Norfloxacin did not adversely affect the fertility of male and female mice at oral doses up to 500mg/kg/day.

Use in pregnancy. (Category B3)

Norfloxacin has been shown to produce embryonic loss in cynomolgus monkeys when given in doses of 150mg/kg/day with peak plasma levels that are two to three times those obtained in humans. There has been no evidence of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 100 to 800mg/kg/day. There were no adequate and well controlled studies in pregnant women. Since norfloxacin, like other medicines in this class, causes arthropathy in immature animals, it should not be used in pregnant women (see PRECAUTIONS).

Australian Pregnancy Categorisation – Category B3. Drugs which have been taken by only a limited number of pregnant women and women of childbearing age without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

Use in lactation

It is not known whether norfloxacin is excreted in human milk. When a 200mg dose of norfloxacin was administered to breastfeeding mothers, norfloxacin was not detected in human milk. However, because the dose studied was low, because other medicines in this class are secreted in human milk, and because of the potential for serious adverse reactions from norfloxacin in breastfed infants, a decision should be made to discontinue breastfeeding or to discontinue the medicine at least 24 to 48 hours before restarting breastfeeding, taking into account the importance of the medicine to the mother.

Use in children

As with other quinolones, norfloxacin has been shown to cause arthropathy in immature animals. The safety of norfloxacin in children has not been adequately explored and therefore norfloxacin is not to be used in children less than 18 years of age.

Effect on ability to drive or operate machinery

Norfloxacin may cause dizziness or lightheadedness; therefore, patients should know how they react to norfloxacin before they operate a vehicle or machinery or engage in activities requiring mental alertness and coordination.

Instructions to patients

Patients should be advised to take Norfloxacin Sandoz one hour before or two hours after a meal. Patients should also be advised to drink fluids liberally and not to take antacids concomitantly or within two hours after dosing.

INTERACTIONS WITH OTHER MEDICINES

Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.

The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonise the antibacterial effect of norfloxacin in the urinary tract.

Quinolones, including norfloxacin, have been shown *in vitro* to inhibit CYP1A2. Concomitant use with drugs metabolised by CYP1A2 (e.g. caffeine, clozapine, ropinirole, tacrine, theophylline, tizanidine) may result in increased substrate drug concentrations when given in usual doses. Patients taking any of these drugs concomitantly with norfloxacin should be carefully monitored.

Elevated plasma levels of theophylline have been reported with concomitant quinolone use. There have been rare reports of theophylline related side effects in patients on concomitant therapy with norfloxacin and theophylline. Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.

Elevated serum levels of cyclosporin have been reported with concomitant use with norfloxacin. Therefore, cyclosporin serum levels should be monitored and appropriate cyclosporin dosage adjustments made when these medicines are used concomitantly.

Quinolones, including norfloxacin, may enhance the effects of the oral anticoagulant warfarin or its derivatives (e.g. phenprocoumon, acenocoumarol) and phenindione or similar agents. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.

The concomitant administration of quinolones including norfloxacin with glibenclamide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycaemia. Therefore, monitoring of blood glucose is recommended when these agents are coadministered.

Multivitamins, calcium preparations, products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with or within two hours of the

administration of norfloxacin because they may interfere with absorption, resulting in lower serum and urine levels of norfloxacin.

Videx (didanosine) chewable/buffered tablets or the paediatric powder for oral solution should not be administered concomitantly with, or within two hours of, the administration of norfloxacin because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.

Some quinolones, including norfloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life, that may lead to accumulation of caffeine in plasma when products containing caffeine are consumed while taking norfloxacin.

The concomitant administration of a nonsteroidal anti-inflammatory drug (NSAID) with a quinolone, including norfloxacin, may increase the risk of central nervous system (CNS) stimulation and convulsive seizures. Therefore, Norfloxacin Sandoz should be used with caution in individuals receiving NSAIDs concomitantly.

Animal data have shown that quinolones in combination with fenbufen can lead to convulsions. Therefore, concomitant administration of quinolones and fenbufen should be avoided.

Lowered bioavailability of mycophenolic acid was observed in healthy volunteers receiving combined treatment with norfloxacin and metronidazole.

ADVERSE EFFECTS

In clinical trials, norfloxacin was generally well tolerated. The incidence of subjects reporting medicine related adverse experiences in clinical trials involving 1,127 subjects was 3.4%. However, the overall incidence was 10.7% and the figures below were calculated without reference to medicine relationship. Most adverse reactions occur within the first few days of therapy.

The most common adverse experiences (1 to 3%) were either gastrointestinal or neurological: nausea 2.8%, headache 2.7% and dizziness 1.8%.

Additional reactions (0.3 to 1%) were: fatigue, rash, abdominal pain, dyspepsia, somnolence, depression, insomnia, constipation, flatulence and heartburn.

Less frequent reactions included: dry mouth, diarrhoea, fever, vomiting, erythema, euphoria, anxiety, irritability, hallucinations, altered taste, vaginal swelling and tendonitis.

Visual disturbances have been reported with medicines in this class.

Abnormal laboratory values observed in these 1,127 subjects in clinical trials were eosinophilia 1.8%, elevation of ALT and AST (1.8%), increased alkaline phosphatase (1.4%), and decreased white blood cell or neutrophil count (1.2%). Those occurring

less frequently included increased serum urea, serum creatinine and LDH, and decreased haematocrit.

Postmarketing

The following additional adverse effects have been reported since the medicine was marketed.

Hypersensitivity reactions. These include angioedema, urticaria, dyspnoea, arthritis, myalgia, arthralgia, anaphylaxis, interstitial nephritis, vasculitis, drug rash with eosinophilia and systemic symptoms (DRESS syndrome).

Skin. Photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, pruritus, and leukocytoclastic vasculitis.

Central nervous system. Convulsions, tremors, myoclonus, confusion, paraesthesia, polyneuropathy including Guillain-Barre syndrome, hypoaesthesia, psychic disturbances including psychotic reactions.

Liver and gastrointestinal tract. Pseudomembranous colitis, pancreatitis (rare), hepatitis, including jaundice and cholestatic jaundice, elevated liver function tests.

Musculoskeletal. Tendonitis, tendon rupture, possible exacerbation of myasthenia gravis, elevated creatine kinase (CK), muscle spasms.

Haematological. Agranulocytosis, thrombocytopenia, haemolytic anaemia, sometimes associated with glucose-6-phosphate dehydrogenase deficiency.

Genitourinary. Vaginal candidiasis

Renal function. Renal failure

Metabolic. Dysglycaemia

Special senses. Dysgeusia, visual disturbances, hearing loss

Causal relationship unknown. A definite causal relationship could not be established with regard to the following adverse effects: conjunctivitis, eye pain/irritation, and asthenia. On very rare occasions, prolonged QTc interval and ventricular arrhythmia (including torsades de pointes), hypertonia, ataxia, dysarthria, dysphasia, haemophthalmia, nystagmus, periorbital erythema and proteinuria have been reported.

DOSAGE AND ADMINISTRATION

Norfloxacin Sandoz tablets should be taken one hour before or two hours after a meal with a glass of water. Patients receiving Norfloxacin Sandoz should be well hydrated. Multivitamins, calcium preparations, other products containing iron or zinc, antacids containing magnesium and aluminium, sucralfate or didanosine (Videx)

chewable/buffered tablets or the paediatric powder for oral solution, should not be taken within two hours of administration of Norfloxacin Sandoz (see PRECAUTIONS).

Urinary tract infection

Normal renal function. The recommended dosage of Norfloxacin Sandoz for the treatment of urinary tract infection is 400mg twice daily for seven to ten days.

For uncomplicated lower urinary tract infections, the recommended dosage is 400mg twice daily for three days. In one study of uncomplicated lower urinary tract infections, treatment for seven days resulted in somewhat better eradication rates than treatment for three days.

For suppression in chronic, recurrent urinary tract infection, 400mg twice daily may be administered for four to twelve weeks.

Maximum total daily dosage should not exceed 800mg.

Impaired renal function. Norfloxacin Sandoz may be used for the treatment of urinary tract infections in patients with renal insufficiency. In patients with a creatinine clearance rate of 30mL/minute/1.73m² or less, the recommended dosage is one tablet (400mg) once daily for the duration given above. At this dosage, the urinary concentration exceeds the MICs for most urinary pathogens susceptible to norfloxacin, even when the creatinine clearance is less than 10mL/minute/1.73m². However, such patients should be observed carefully for adverse effects due to possible medicine retention.

When only the serum creatinine level is available, the following formula (based on sex, weight and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function. Please refer to equation 1.

Equation 1. Calculation of creatinine clearance (ml/min)

$$\text{Males:} = \frac{(\text{Weight in kg}) \times (140 - \text{age})}{(72) \times \text{serum creatinine (mmol/L)}} \times 0.0885$$

$$\text{Females} = (0.85) \times (\text{above value})$$

Use in the elderly. Elderly patients with a creatinine clearance of greater than 30mL/minute/1.73m² should receive the dosages recommended under Normal renal function.

Elderly patients with a creatinine clearance of 30mL/minute/1.73m² or less should receive 400mg once daily as recommended under Impaired renal function.

Gastrointestinal infection (Shigellosis, traveller's diarrhoea)

The recommended dosage is 400mg twice daily for five days.

OVERDOSAGE

The acute oral LD50 values in male and female mice and male and female rats were greater than 4g/kg.

Contact the Poisons Information Centre on 13 11 26 for advice on management of overdose.

Treatment

In the event of acute overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be observed carefully and given symptomatic and supportive treatment.

Adequate hydration must be maintained.

PRESENTATION AND STORAGE CONDITIONS

Norfloxacin Sandoz 400mg film-coated tablets - oval white tablets.
Available in aluminium/aluminium blisters of 6* or 14 tablets per cardboard box.

* Not currently marketed in Australia

Store below 25 °C.

NAME AND ADDRESS OF THE SPONSOR

Sandoz Pty Ltd
ABN 60 075 449 553
54 Waterloo Road
Macquarie Park, NSW 2113
Australia
Tel: 1800 634 500

POISON SCHEDULE OF THE MEDICINE

Schedule 4 – Prescription Only Medicine

Date of first inclusion in the Australian Register of Therapeutic Goods (the ARTG): 4/12/2000

Date of the most recent amendment: 21/01/2016